Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.58 |
| ▸ | NPC1 | O15118 | 5/20 | 0.51 |
| ▸ | HTT | P42858 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | JAK2 | O60674 | 1/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL214930 | 0.82 | LMNA (0.51) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL2871030 | 0.81 | SMN1; SMN2 (0.57) | RAB9ANPC1HTTMAPTALDH1A1 | |
| SCHEMBL12380464 | 0.81 | HCAR3 (0.60) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL24101021 | 0.80 | HCAR3 (0.67) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3123525 | 0.80 | NPC1 (0.50) | RAB9ANPC1HTTMAPTALDH1A1 | |
| SCHEMBL4919298 | 0.80 | RAB9A (0.73) | RAB9ANPC1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL23320436 | 0.79 | RAB9A (0.54) | RAB9ANPC1HTTMAPTALDH1A1 | |
| SCHEMBL10781478 | 0.78 | RAB9A (0.50) | RAB9ANPC1HTTMAPTALDH1A1 | |
| SCHEMBL1891463 | 0.78 | RAB9A (0.50) | RAB9ANPC1HTTMAPTALDH1A1 | |
| SCHEMBL1615839 | 0.78 | SMN1; SMN2 (0.73) | RAB9ANPC1HTTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513818-B1 | HETEROCYCLIC INHIBITORS OF VEGFR-2 KINASES | BRISTOL MYERS SQUIBB CO (US) | 2010-01-20 | — | — | EP | disclosed |
| US-7547711-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-06-16 | — | — | US | disclosed |
| EP-1513818-A4 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL MYERS SQUIBB CO (US) | 2006-10-04 | — | — | EP | disclosed |
| US-7084160-B2 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-08-01 | — | — | US | disclosed |
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | BORZILLERI ROBERT M | 2006-06-22 | — | — | US | disclosed |
| EP-1513818-A2 | HETEROCYCLIC INHIBITORS OF KINASES | Bristol-Myers Squibb Company (US) | 2005-03-16 | — | — | EP | disclosed |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | BRISTOL-MYERS SQUIBB COMPANY | 2004-04-22 | — | — | US | disclosed |
| WO-2004001059-A2 | HETEROCYCLIC INHIBITORS OF KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135576-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | RAB9A 2178/4885NPC1 3873/4885HTT 3063/4885 |
| US-20040077696-A1 | Heterocyclic inhibitors of kinases | FGFR1, FLT1, FGFR2 | RAB9A 2003/4885NPC1 3732/4885HTT 3342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.